{"id":"venlafaxine-xr-plus-aripiprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL2219425","moleculeType":"Small molecule","molecularWeight":"660.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Venlafaxine XR is an SNRI that increases synaptic levels of serotonin and norepinephrine by blocking their reuptake transporters, treating depression and anxiety. Aripiprazole is an atypical antipsychotic that stabilizes dopamine signaling through partial agonism at D2 receptors, reducing psychotic symptoms and augmenting antidepressant efficacy. This combination is used in treatment-resistant depression and depression with psychotic features.","oneSentence":"Venlafaxine XR inhibits serotonin and norepinephrine reuptake while aripiprazole acts as a dopamine D2 receptor partial agonist, together addressing both depressive and psychotic symptoms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:15:02.936Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder, treatment-resistant"},{"name":"Major depressive disorder with psychotic features"}]},"trialDetails":[{"nctId":"NCT02977299","phase":"PHASE4","title":"Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-05-01","conditions":"Treatment Resistant Major Depressive Disorder","enrollment":278},{"nctId":"NCT00892047","phase":"PHASE4","title":"Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2009-08","conditions":"Depression","enrollment":468}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["effexor XR, abilify"],"phase":"marketed","status":"active","brandName":"venlafaxine XR plus aripiprazole","genericName":"venlafaxine XR plus aripiprazole","companyName":"University of Pittsburgh","companyId":"university-of-pittsburgh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Venlafaxine XR inhibits serotonin and norepinephrine reuptake while aripiprazole acts as a dopamine D2 receptor partial agonist, together addressing both depressive and psychotic symptoms. Used for Major depressive disorder, treatment-resistant, Major depressive disorder with psychotic features.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}